search URL:,https://patents.google.com/?assignee=MINERVA+NEUROSCIENCES+INC
id,title,assignee,inventor/author,priority date,filing/creation date,publication date,grant date,result link,representative figure link
US-9732059-B2,Methods of use of cyclic amide derivatives to treat schizophrenia ,"Minerva Neurosciences, Inc.","Remy Henri Luthringer, Lorenzo Pellegrini, Argeris N. Karabelas",2010-07-20,2011-07-20,2017-08-15,2017-08-15,https://patents.google.com/patent/US9732059B2/en,
US-10258614-B2,Compositions and methods for treating schizophrenia ,"Minerva Neurosciences, Inc.","Remy Luthringer, Nadine Noel, Sandra Werner",2014-12-02,2017-07-17,2019-04-16,2019-04-16,https://patents.google.com/patent/US10258614B2/en,https://patentimages.storage.googleapis.com/93/34/a1/e06c5765458625/US10258614-20190416-D00001.png
EP-2595484-B1,Use of cyclic amide derivatives to treat sleep disorders ,"Minerva Neurosciences, Inc.","Remy Henri Luthringer, Lorenzo Pellegrini, Argeris N. Karabelas",2010-07-20,2011-07-20,2017-10-18,2017-10-18,https://patents.google.com/patent/EP2595484B1/en,
US-2013274290-A1,Methods of use of cyclic amide derivatives to treat sigma receptor mediated disorders ,"Cyrenaic Pharmaceuticals, Inc.","Remy Henri Luthringer, Lorenzo Pellegrini, Argeris N. Karabelas",2010-07-20,2011-07-20,2013-10-17,,https://patents.google.com/patent/US20130274290A1/en,
AU-2014209200-B2,Use of phenoxypropylamine compounds to treat depression ,"Minerva Neurosciences, Inc.","Argeris Karabelas, Remy LUTHRINGER, Lorenzo Pellegrini",2013-01-24,2014-01-24,2018-11-01,2018-11-01,https://patents.google.com/patent/AU2014209200B2/en,
US-2019038561-A1,Gastro-resistant controlled release oral dosage forms ,"Minerva Neurosciences, Inc.","Jay SAOUD, Remy Luthringer, Sandra Werner, Nadine Noel, Emmanuelle Georgi",2017-06-21,2018-06-21,2019-02-07,,https://patents.google.com/patent/US20190038561A1/en,https://patentimages.storage.googleapis.com/06/d1/e0/9a4d88c53ac6c8/US20190038561A1-20190207-D00001.png
EP-3463356-A1,Compositions and methods for treating negative symptoms in non-schizophrenic patients ,"Minerva Neurosciences, Inc.","Remy LUTHRINGER, Michael Davidson",2016-05-25,2017-05-23,2019-04-10,,https://patents.google.com/patent/EP3463356A1/en,
EP-3463357-A1,"(2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders ","Minerva Neurosciences, Inc.",Remy LUTHRINGER,2016-05-25,2017-05-23,2019-04-10,,https://patents.google.com/patent/EP3463357A1/en,
